This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

This study has been completed.
Information provided by:
George Washington University Identifier:
First received: February 29, 2008
Last updated: July 7, 2011
Last verified: February 2009
This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy. All patients will receive concomitant therapy with Truvada. It is hypothesized that (1) the raltegravir regimen will have similar efficacy in terms of both viral suppression as well as increases in CD4 cell counts and (2) raltegravir will have significantly less impact on plasma lipids, lipoproteins and lipoproteins subtypes, compared with lopinavir/ritonavir.

Condition Intervention Phase
HIV Infections Drug: Raltegravir Drug: Lopinavir/Ritonavir Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy

Resource links provided by NLM:

Further study details as provided by George Washington University:

Primary Outcome Measures:
  • Absolute change in CD4 cell counts and HIV RNA. [ Time Frame: 24 and 48 weeks ]

Secondary Outcome Measures:
  • Change is plasma lipids, lipoproteins and lipoprotein subtypes. [ Time Frame: 24 weeks ]

Estimated Enrollment: 80
Study Start Date: February 2008
Study Completion Date: June 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Raltegravir Drug: Raltegravir
1 400mg tablet twice a day
Active Comparator: Lopinavir/Ritonavir Drug: Lopinavir/Ritonavir
2 tablets twice a day


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented HIV infection confirmed by western blot or HIV RNA.
  2. At least 18 years of age.
  3. Less than 1 week of prior antiretroviral therapy.
  4. In the opinion of the investigator, patients should be clinically stable. Patients may be on chronic suppressive therapy for opportunistic infections such as MAC or CMV.
  5. Patients who are of reproductive potential agree to use an acceptable method of birth control throughout the study. Acceptable methods include an intrauterine device (IUD), diaphragm with spermicide, condoms, or abstinence.
  6. HIV RNA > 5000 copies/ml. No restriction on CD4 cell count.
  7. A negative urine pregnancy test on the day of initiation of therapy.

Exclusion Criteria:

  1. Prior treatment with >1week of antiretroviral therapy.
  2. Patient requires or is anticipated to require any of the prohibited medications noted in the protocol.
  3. HIV RNA < 5000 prior to receiving therapy.
  4. Baseline resistance to any of the study regimen drugs on genotype testing.
  5. Patients with acute hepatitis due to any cause or clinically significant chronic liver disease.
  6. Patient with severe renal insufficiency defined as a calculated creatinine clearance at time of screening <30mL/min, based on the Cockcroft-Gault equation which is as follows (and 0.85X this value for females): Clcr(mL/min) = (l40-age) x weight (in kg)72 x serum creatinine (mg/dL).
  7. Patient has a condition (including but not limited to alcohol or other substance abuse) which in the opinion of the investigator would interfere with patient compliance or safety.
  8. A female patient who is pregnant, breast-feeding, or expecting to conceive or donate eggs during the study; or a male patient who is planning to impregnate or provide sperm donation during the study is excluded.
  9. Inability to obtain signed informed consent from a patient age 18 or older.
  10. Patient has significant hypersensitivity or other contraindication to any of the components of the study drug.
  11. Patients who should be treated for hyperlipidemia as per NCEPIII guidelines and patients who are currently receiving lipid-lowering therapy are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00632970

United States, District of Columbia
George Washington University Medical Faculty Associates
Washington DC, District of Columbia, United States, 20037
Sponsors and Collaborators
George Washington University
Principal Investigator: Gary Simon, MD, PhD George Washington University
  More Information

Responsible Party: Gary Simon, MD PhD, George Washington University Medical Center Identifier: NCT00632970     History of Changes
Other Study ID Numbers: GS001
Study First Received: February 29, 2008
Last Updated: July 7, 2011

Keywords provided by George Washington University:

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Raltegravir Potassium
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
HIV Integrase Inhibitors
Integrase Inhibitors processed this record on June 23, 2017